Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Cord Blood Transplantation for High-Risk Hematologic Malignancies
NCT06013423Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jul 2024
- Primary completion
- Oct 2031
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood in hematologic malignancy, sponsored by Fred Hutchinson Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
umbilical cord blood
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT06013423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013423.